Form 4: ELTP EVP Operations Sells Shares, Exercises Options

Elite Pharmaceuticals' EVP Operations, Doug Plassche, reported selling 500,000 shares and exercising 2.5 million stock options, increasing direct common stock ownership.

Summary

• Doug Plassche, EVP Operations of Elite Pharmaceuticals Inc. (ELTP), reported transactions on August 22, 2025, and August 25, 2025.
• On August 22, 2025, 500,000 shares of common stock were sold at a weighted average price of $0.5243 per share, with prices ranging from $0.52 to $0.56.
• Following this sale, direct beneficial ownership of common stock was 1,800,000 shares.
• On August 25, 2025, 2,500,000 stock options were exercised at a price of $0.03 per share.
• These stock options were fully vested and exercisable as of the transaction date.
• After the option exercise, direct beneficial ownership of common stock increased to 4,300,000 shares.
• The reporting person continues to hold 2,500,000 derivative securities (stock options) with an expiration date of January 3, 2033.

Sentiment

Score: 6

Explanation: While there was a sale of common stock, the significant exercise of options at a low price, leading to a net increase in direct common stock ownership, suggests a slightly positive outlook from the executive.

Positives

• EVP Operations exercised 2,500,000 stock options at a low exercise price of $0.03, indicating a potential belief in future stock appreciation.
• The exercise of options resulted in a net increase of 2,000,000 shares in direct common stock ownership for the EVP Operations (2,500,000 acquired minus 500,000 sold).

Negatives

• EVP Operations sold 500,000 shares of common stock at a weighted average price of $0.5243.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.52 to $0.56, inclusive.
• The reporting person undertakes to provide to Elite Pharmaceuticals, any security holder of Elite Pharmaceuticals, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
• All of the stock options were fully vested and exercisable as of the transaction date.

Industry Context

This insider transaction report provides specific details about an executive's stock movements and does not offer broader industry context or competitive analysis.

Stakeholder Impact

• Shareholders may interpret the executive's net increase in direct common stock ownership as a sign of confidence in the company's future prospects, despite the concurrent sale of some shares.

Key Dates

Keywords

Elite Pharmaceuticals, ELTP, Form 4, Insider Trading, Stock Options, EVP Operations, Doug Plassche, Share Sale, Option Exercise